Vicente LLP Federal and International Cannabis and Psychedelics Law and Policy Update: November 2023
Nov 10, 2023
Federal and international law and policy insights, news and events from Vicente LLP.
Nov 10, 2023
Federal and international law and policy insights, news and events from Vicente LLP.
By Shawn Hauser
Aug 31, 2023
The federal government formally acknowledged the medical use and low potential of abuse for cannabis, with the US Department of Health and Human Services recommending that cannabis be rescheduled to Schedule III under the Controlled Substances Act. While placement in Schedule III still criminalizes commercial cannabis activity at the federal level, it is a significant step on the path to ending prohibition. This rescheduling would eliminate the application of 280E tax penalties, reduce the level of criminal liability for cannabis-related activity, reduce barriers to research, legitimize the industry through gaining credibility and engagement by physicians and the medical community, and support a growing industry for the American economy.
Jul 12, 2023
Mushrooms are having a moment! Watch this session to learn about current and future business opportunities in the growing world of adaptogenic and functional mushrooms.
By Charles Alovisetti, Sahar Ayinehsazian
Mar 3, 2023
Given the wide variety of available functional/adaptogenic mushroom product forms, producers and consumers should be aware of the significant differences in regulations for food, food additives, and dietary supplements.
By Catie Wightman
Feb 13, 2023
In recent years, several CBD companies faced product liability lawsuits brought by consumers. Many of these cases were dismissed without prejudice or stayed until the FDA takes action to regulate CBD products. Now that the FDA said it will not take action to regulate CBD, could these cases be revived?
Feb 9, 2023
The FDA decided not to regulate CBD, denied three citizen petitions requesting CBD rulemaking or other FDA action, and announced it is now up to Congress to step in. Watch this webinar and learn what this means for your hemp-derived cannabinoids business.
By Andrea Golan
Jan 6, 2023
Minnesota hemp companies are being sued by the Minnesota Board of Pharmacy for selling high-THC hemp-derived edibles that allegedly contained 100 milligrams of hemp-derived THC per gummy bear and were intentionally marketed in a manner that is appealing to children. What standards may lower consumer safety risks for these products?
By Catie Wightman, Michelle Bodian
Nov 30, 2022
On November 21, 2022, the FDA issued five warning letters to companies selling CBD, Delta-8, and other hemp products for humans and pets.
By Shane Pennington
Nov 9, 2022
What outcomes are possible from the impending administrative process to reconsider cannabis’s schedule I status? What are the implications of those various possible outcomes? And how should we all proceed in light of it all?
By Shane Pennington
Oct 21, 2022
To appreciate the gravity of the President’s scheduling directive and what could happen next, you need to understand (1) how the administrative process the President has set in motion will actually work and (2) how the agencies in charge have used it to affirm and reaffirm cannabis’s schedule I1 status repeatedly throughout the Comprehensive Drug Abuse Prevention and Control Act of 1970’s (“CSA”) history. Those topics are covered in this article.
By Shane Pennington
Oct 21, 2022
President Biden’s scheduling directive is enormously important. In fact, if permitted to run its course, it could revolutionize federal drug control law to a far greater degree than any of the many pending cannabis legalization bills.
Oct 17, 2022
Reserve your seat for Dutchie and Vicente Sederberg LLP’s co-hosted webinar about insurance and cannabis businesses on October 20!
By Catie Wightman, Ariane Beckman
Aug 11, 2022
The FDA is cracking down on companies making unlawful drug or disease claims about their products relating to CBD by recently issuing several warning letters to address these compliance violations.
Jul 28, 2022
Update on hemp-related legislation and rulemaking, regulatory changes, and other noteworthy hemp news and events.
Jun 1, 2022
In VS's inaugural Impact Report, we reflect on our work over the past year, celebrate our commitment to community, and look forward to a future of positive, meaningful, and measurable impact.
May 17, 2022
Watch this VS live session for a timely discussion exploring intoxicating hemp-derived products.
By Michelle Bodian, Shawn Hauser, Catie Wightman
May 5, 2022
For the first time ever, the FDA issued warning letters to companies selling products containing hemp-derived Delta-8 THC. Notably, this is the first time the FDA has specifically enforced against Delta-8 products. Read this for key takeaways from these warning letters.
Apr 21, 2022
Sen. Schumer and Antonio Valdez of the National Hispanic Cannabis Council co-authored a guest column for Univision about how Latinos can benefit from the cannabis economy.
Apr 15, 2022
Kim Napoli was recognized by her peers during the 2022 NECANN Conference Community Awards
Apr 4, 2022
Update on hemp-related legislation and rulemaking, regulatory changes, and other noteworthy hemp news and events.
By Michelle Bodian, Jace Pohlman
Mar 30, 2022
The FDA and FTC are working together to target fraudulent COVID-19 claims made by CBD companies. Seven CBD product companies received warning letters. Read this article for a look into what to do—or not do—to avoid a warning.
Dec 27, 2021
Watch this session to learn accounting best practices for cannabis businesses and how to prepare for year-end. With a focus on social equity operators, this session will advise on risk and opportunity related to the financial side of cannabis operations, as well as how to navigate the complexities of 280E.
Dec 4, 2021
VS attorney Sahar Ayinehsazian is slated to speak at the National Asian Pacific American Bar Association (NAPABA) Convention on December 10, 2021.
Sep 20, 2021
Kim Napoli was nominated by her peers for two awards at this years' NECANN Conference Community Awards and ultimately voted the Champion of Corporate Responsibility!
Sep 16, 2021
Find Kim Napoli on the Education Village Stage at 3 p.m. Joining Kim are Blake Mensing, Robert Jeffrey, Dick Evans and Jason Ortiz.
Aug 26, 2021
Watch this session for a dive into key elements of the regulations and an engaging discussion with special guests from the NJ CannaBusiness Association, the NJ League of Municipalities, and the US Cannabis Council.
Aug 25, 2021
Vote for the panel "Sue 'n the DEA: Breaking the 50-Year NIDA Monopoly," featuring Shane Pennington to be included in SXSW 2022!
Aug 25, 2021
Vote for the panel "Sue 'n the DEA: Breaking the 50-Year NIDA Monopoly," featuring Shane Pennington to be included in SXSW 2022!
By Shawn Hauser
Aug 25, 2021
Recent NDIN notification objections from the FDA give us more insight into the agency's factors differentiating "full spectrum" hemp from CBD.
Aug 11, 2021
With a new Administration and Congress, changes in personnel at FDA, and new safety data being published, is 2021 the year when CBD will come out from under the FDA shadows to be legally marketed in all 50 states?
By Shawn Hauser
Jul 22, 2021
In this article, we’ll look at the history of CBD regulation in the United States, the trends that are dominating CBD regulation in 2021, and some of the state-specific regulations in the largest states.
Jul 6, 2021
Marc Ross spoke with Heather Allman of Cannabis Law Report about what ESG is and why it's important for the cannabis industry.
Jun 15, 2021
Watch this recorded session to meet the new VS Impact & ESG team, learn more about this emerging business priority, and how to start planning and measuring your ESG practice – including Corporate Social Responsibility programs, meaningful Diversity, Equity & Inclusion efforts, environmental sustainability, and community and employee engagement.
By Charles Alovisetti, Sally Kent Peebles
Jan 15, 2021
As more law firms are fielding client questions about cannabis industry transactions, it can be challenging for corporate counsel to identify when they need cannabis regulatory counsel.
By Vicente Sederberg LLP
Dec 18, 2020
Vicente Sederberg attorneys wrote the book on cannabis law — and now you can own it! This comprehensive primer on all things cannabis law is a must-have for anyone seeking to understand the major practical legal issues facing the marijuana and hemp industries.
By Corey Cox
May 28, 2020
The CBD-based medicine, Epidiolex, was descheduled by the DEA and is no longer a controlled substance. What are the implications of this change and what, if anything, does it mean for CBD products in general?
By Charles Alovisetti, Elliot Choi, Sahar Ayinehsazian, Corey Cox
May 5, 2020
The continuing growth of the cannabis and hemp industries has given rise to the need for specifically tailored due diligence.